Advertisement

Chronic Lymphocytic Leukemia

  • O. M. Odenike
Chapter
  • 110 Downloads

Abstract

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world, accounting for about 30% of all leukemias reported in the SEER (Surveillance Epidemiology and End Results Program) database [1]. Approximately 8100 new cases were projected in the United States for the year 2000 [2].

Keywords

Clin Oncol Chronic Lymphocytic Leukemia Minimal Residual Disease Mantle Cell Lymphoma Chronic Lymphocytic Leukemia Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hernandez JA, Land KJ, Mckenna RW (1995) Leukemias, myeloma and other lymphoretic-ular neoplasms. Cancer 75: 381–394PubMedCrossRefGoogle Scholar
  2. 2.
    Greenlee RT, Murray T, Bolden S et al (2000) Cancer statistics 2000. Ca Cancer J Clin 50:7–33PubMedCrossRefGoogle Scholar
  3. 3.
    Yanagihara ET, Blaisdell RK, Hayashi T, Lukes RJ (1989) Malignant lymphoma in Japanese: a retrospective morphologic survey. Hematol Oncol 7:219–232PubMedCrossRefGoogle Scholar
  4. 4.
    Cuttner J (1992) Increased incidence of hematological malignancies in first-degree relatives of patients with chronic lymphocytic leukemia. Cancer Invest 10:103–109PubMedCrossRefGoogle Scholar
  5. 5.
    Muller-Hermelink HK, Catovsky D, Montserrat E, Harris NL (2001) Chronic lymphocytic leukemia/small lymphocytic lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) World Health Organization classification of tumours. IARC Press, LyonGoogle Scholar
  6. 6.
    Matutes E, Owusu-Ankomah K, Morilla R, Garcia MJ, Houlihan A, Que TH, Catovsky D (1994) The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 8:1640–1645PubMedGoogle Scholar
  7. 7.
    Moreau EJ, Matutes E, A’Hearn RP, Morilla AM, Morilla RM, Owusu-Ankomah KA, Seon BK, Catovsky D (1997) Improvement of the chronic lymphocytic leukemia scoring system with the mono-clonal antibody SN8 (CD79b). Am J Clin Pathol 108:378–382PubMedGoogle Scholar
  8. 8.
    Dohner H, Stilgenbauer S, Benner A et al (2000) Genetic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910–1916PubMedCrossRefGoogle Scholar
  9. 9.
    Rai KR, Sawitsky AM, Cronkite EP et al (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46:219–234PubMedGoogle Scholar
  10. 10.
    Binet JL, Auquier A, Dighiero G et al (1981) A new prognostic classification of chronic lymphocytic derived from a multivariate survival analysis. Cancer 48:198–206PubMedCrossRefGoogle Scholar
  11. 11.
    Dighiero G, Binet J-L (2000) When and how to treat chronic lymphocytic leukemia. N Engl J Med 343:1799–1801PubMedCrossRefGoogle Scholar
  12. 12.
    Montserrat E, Vinolus E, Reverter JC et al (1988) Natural history of chronic lymphocytic leukemia; on the progression and prognosis of early clinical stages. Nouv Rev Fr Hematol 30:359–361PubMedGoogle Scholar
  13. 13.
    Rozman C, Montserrat E, Rodriquez-Fernandez JM et al (1984) Bone marrow histologic pattern — the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 64: 642–648PubMedGoogle Scholar
  14. 14.
    Molica S, Levato D, Cascavillla N et al (1999) Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B cell chronic lymphocytic leukemia. Eur J Haematol 62:117–122PubMedCrossRefGoogle Scholar
  15. 15.
    Damle JN, Wasil T, Fais F et al (1999) IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840–1847PubMedGoogle Scholar
  16. 16.
    Ibrahim S, Keating M, Do K-A et al (2001) CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 98:181–186PubMedCrossRefGoogle Scholar
  17. 17.
    Dohner H, Fischer K, Bentz M et al (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85: 1580–1589PubMedGoogle Scholar
  18. 18.
    Bartik MM, Welker D, Kay NE (1998) Impairments in immune cell function in B-cell chronic lymphocytic leukemia. Semin Oncol 25:27–33PubMedGoogle Scholar
  19. 19.
    Cheson BD, Bennett JM, Kay N et al (1996) National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87:4990–4997PubMedGoogle Scholar
  20. 20.
    Hamblin TJ, Oscier DG, Young BJ (1986) Autoimmunity in chronic lymphocytic leukemia. J Clin Pathol 39:713–716PubMedCrossRefGoogle Scholar
  21. 21.
    Robertson LE, Pugh W, O’Brien S et al (1993) Richter’s syndrome: a report on 39 patients. J Clin Oncol 11:1985–1989PubMedGoogle Scholar
  22. 22.
    Dighiero G, Maloum K, Desablens B et al (1998) Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 338:1506–1514PubMedCrossRefGoogle Scholar
  23. 23.
    CLL Trialists Collaborative Group (1999) Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst 91:861–868CrossRefGoogle Scholar
  24. 24.
    Rai KR, Peterson BL, Applebaum FR et al (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750–1757PubMedCrossRefGoogle Scholar
  25. 25.
    Han T, Ezdinli EZ, Shimaoka K, Desai DV (1973) Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia. Cancer 31:502–508PubMedCrossRefGoogle Scholar
  26. 26.
    Raphael B, Andersen JW, Silber R, Oken M, Moore D, Bennett J et al (1991) Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J Clin Oncol 9:770–776PubMedGoogle Scholar
  27. 27.
    French Cooperative Group on Chronic Lymphocytic Leukemia (1990) A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. Blood 75:1422–1455Google Scholar
  28. 28.
    Kimby E, Mellstedt H (1991) Chlorambucil/prednisolone verus CHOP in symptomatic chronic lymphocytic leukemias of B-cell type. Leuk Lymph 4:93–96CrossRefGoogle Scholar
  29. 29.
    Jaksic B, Brugitiatelli M, Krc I, Losonczi H, Holowiecki J, Planine-Peraica A et al (1997) High-dose chlorambucil versus Binet’s modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna. Cancer 79:2107–2114PubMedCrossRefGoogle Scholar
  30. 30.
    French Cooperative Group on Chronic Lymphocytic Lukaemia (1986) Effectiveness of “CHOP” regimen in advanced B-cell chronic lymphocytic leukemia. Lancet 1:1346–1349Google Scholar
  31. 31.
    Keating MJ, O’Brien S, Lerner S et al (1998) Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92:1165–1171PubMedGoogle Scholar
  32. 32.
    Sorensen JM, Vena DA, Fallavollita A et al (1997) Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report. J Clin Oncol 15:458–465PubMedGoogle Scholar
  33. 33.
    Keating MJ (1999) Chronic lymphocytic leukemia. Semin Oncol 26:107–114PubMedGoogle Scholar
  34. 34.
    O’B rien SM, Kantarjian HM, Cortes J et al (2001) Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia J Clin Oncol 19:1414–1420PubMedGoogle Scholar
  35. 35.
    Flinn IW, Byrd JC, Morrison C et al (2000) Fludarabine and cyclophosphamide with filgastrim support in patients with previously untreated indolent lymphoid malignancies. Blood 96:71–75PubMedGoogle Scholar
  36. 36.
    Byrd JC, Peterson BL, Park K et al (2001) Concurrent rituximab and fludarabine has a higher complete response rate than sequential treatment in untreated chronic lymphocytic leukemia (CLL) patients: results from CALGB 9712 (abstract). Blood 98:772AGoogle Scholar
  37. 37.
    O’B rien S, Kantarjian H, Beran M et al (1993) Results of fludarabine and prednisolone therapy in 264 patients with chronic lymphocytic leukemia with a multi-variate analysis-derived prognostic model for response to treatment. Blood 82:1695–1700PubMedGoogle Scholar
  38. 38.
    The French Cooperative Group on CLL (1996) Multicenter prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia. Lancet 347:1432–1438Google Scholar
  39. 39.
    Osterborg A, Dyer MJS, Bunjes D et al (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 96:617–619Google Scholar
  40. 40.
    Keating MJ, Byrd J, Rai KR et al (1999) Multicenter study of Campath-1H in patients with CLL refractory to fludarabine. Blood 94:705AGoogle Scholar
  41. 41.
    Winkler U, Jensen M, Manzke O et al (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDECC2B8). Blood 94:2217–2224PubMedGoogle Scholar
  42. 42.
    Byrd JC, Murphy T, Howard RS et al (2001) Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19:2153–2164PubMedGoogle Scholar
  43. 43.
    O’B rien SM, Kantarjian H, Thomas DA et al (2001) Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19:2165–2170PubMedGoogle Scholar
  44. 44.
    Bryd JC, Shinn CA, Pearson MD et al (1999) Hu1D10 induces apoptosis in vitro in human chronic lymphocytic leukemia cells independent of complement-mediated lysis but requires Fc receptor ligation (abstract). Blood 94:314AGoogle Scholar
  45. 45.
    Byrd JC, Shinn C, Waslenko JK et al (1998) Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence upon functional p53. Blood 92: 3804–3816PubMedGoogle Scholar
  46. 46.
    Forbes IJ, Xalewski PD, Giannaksis C et al (1994) Induction of apoptosis in chronic lymphocytic leukemia cells and prevention by phorbol ester. Exp Cell Res 198:397–400Google Scholar
  47. 47.
    Katako K, Mohammad RM, Dugan MC et al (1998) Sequential treatment of chronic lymphocytic leukemia with bryostatin 1 and 2-chlorodeoxyadenosine: a pre-clinical study. Clin Cancer Res 4:445–453Google Scholar
  48. 48.
    Varterasain M, Eilender D, Mohammad R et al (1998) A phase I trial of bryostatin 1 in relapsed non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. J Clin Oncol 16:55–62Google Scholar
  49. 49.
    Reed JC (1998) Molecular biology of chronic lymphocytic leukemia. Semin Oncol 25:11–18PubMedGoogle Scholar
  50. 50.
    Kitada S, Takayama S, De Riel K, Tanaka S, Reed JC (1994) Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev 4:71–79PubMedGoogle Scholar
  51. 51.
    Byrd JC, Shinn CA, Raji R et al (1999) Depsipeptide (FR901228): a novel therapeutic agent with selective in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 94:1401–1408PubMedGoogle Scholar
  52. 52.
    Van Besien K, Keralavarma B, Devine S, Stock W (2000) Allogeneic and autologous transplantation for chronic lymphocytic leukemia. Leukemia 15:1317–1325CrossRefGoogle Scholar
  53. 53.
    Rabinowe SN, Soiffer RJ, Gribben JG et al (1993) Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 82:1366–1376PubMedGoogle Scholar
  54. 54.
    Dyer MJ, Kelsey SM, Mackay HJ et al (1997) In vivo “purging” of residual disease in CLL with campath-1H. Br J Haematol 97:669–672PubMedCrossRefGoogle Scholar
  55. 55.
    Berkhan LC, Simpson DR, Raptis A et al (2000) Rituxan in vivo purging of stem-cells for autologous transplantation in chronic lymphocytic leukemia (abstract). Blood 96:186AGoogle Scholar
  56. 56.
    Pavletic ZS, Bierman PJ, Vose JM et al (1998) High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic leukemia. Ann Oncol 9:1023–1026PubMedCrossRefGoogle Scholar
  57. 57.
    Esteve J, Villamor N, Colomer D et al (2001) Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease. Leukemia 15:445–451PubMedCrossRefGoogle Scholar
  58. 58.
    Khouri I, Keating M, Korbling M et al (1998) Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16:2817–2824PubMedGoogle Scholar
  59. 59.
    Schetelig J, Held TK, Bornhauser M et al (2000) Nonmyeloblative stem cell transplant in chronic lymphocytic leukemia from related and unrelated donors (abstract). Blood 96:200AGoogle Scholar
  60. 60.
    Wierda W, O’B rien S, Albitar M et al (2001) Combined fiudarabine, cyclophosphamide and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia (abstract). Blood 98:771ACrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • O. M. Odenike

There are no affiliations available

Personalised recommendations